BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 28003305)

  • 1. Co-occurring Mutations of Tumor Suppressor Genes,
    Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
    Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
    Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
    Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
    Maille E; Brosseau S; Hanoux V; Creveuil C; Danel C; Bergot E; Scherpereel A; Mazières J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Langlais A; Morin F; Levallet G; Zalcman G
    Br J Cancer; 2019 Feb; 120(4):387-397. PubMed ID: 30739911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
    J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
    J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.
    Tranchant R; Quetel L; Montagne F; De Wolf J; Meiller C; De Koning L; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Lung Cancer; 2018 Dec; 126():15-24. PubMed ID: 30527180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
    Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
    Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and characterization of CRISPR/Cas9-mediated NF2
    Wahiduzzaman M; Karnan S; Ota A; Hanamura I; Murakami H; Inoko A; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y
    Cancer Sci; 2019 Jan; 110(1):180-193. PubMed ID: 30417500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LATS2 is a tumor suppressor gene of malignant mesothelioma.
    Murakami H; Mizuno T; Taniguchi T; Fujii M; Ishiguro F; Fukui T; Akatsuka S; Horio Y; Hida T; Kondo Y; Toyokuni S; Osada H; Sekido Y
    Cancer Res; 2011 Feb; 71(3):873-83. PubMed ID: 21245096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
    Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.
    Tallet A; Nault JC; Renier A; Hysi I; Galateau-Sallé F; Cazes A; Copin MC; Hofman P; Andujar P; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Oncogene; 2014 Jul; 33(28):3748-52. PubMed ID: 23975423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses
    Cooper J; Xu Q; Zhou L; Pavlovic M; Ojeda V; Moulick K; de Stanchina E; Poirier JT; Zauderer M; Rudin CM; Karajannis MA; Hanemann CO; Giancotti FG
    Mol Cancer Ther; 2017 Aug; 16(8):1693-1704. PubMed ID: 28468780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
    Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
    Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
    [No Abstract]   [Full Text] [Related]  

  • 19. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
    Edakuni N; Ikuta K; Yano S; Nakataki E; Muguruma H; Uehara H; Tani M; Yokota J; Aizawa H; Sone S
    Oncol Res; 2006; 16(5):235-43. PubMed ID: 17294804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
    Shukuya T; Oyanagi J; Serizawa M; Watanabe M; Yamamoto N; Koh Y
    Anticancer Res; 2020 Apr; 40(4):1867-1874. PubMed ID: 32234874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.